Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking

Abstract

Background: To report acute and late toxicity in prostate cancer patients treated by dose escalated intensity-modulated radiation therapy (IMRT) and organ tracking.

Pelvic symptoms after radiotherapy in prostate cancer: a cross-sectional study

“…This dropped to 28% later in the follow-up period. There were no cases of Grade 4 genitourinary toxicity [14]. In our study, irritative symptoms (urinary urgency and daytime frequency) and nocturia, when considered together, were more frequent in the Post-RT #1 group.…”

“…Ghadjar and collaborators [14] studied the acute and late effects of RT in 39 men with PC. Grade 2 gastrointestinal toxicity (particularly diarrhea, pain, and rectal bleeding) varied from 3% to 8% of cases.…”

Reducing radiation-associated toxicity using online image guidance (IGRT) in prostate cancer patients undergoing dose-escalated radiation therapy

“…Notably, 20% of the IGRT patients did not complain of any GU symptoms, compared to 11% of the non-IGRT patients (p = 0.07). As reported by Ghadjar et al, 4 acute urinary symptoms occur in up to 56% of cases. Severe GU side effects were rare, occurring in 9% of the non-IGRT group and in 5% of the IGRT group, without any grade 4 reactions.…”

“…These results corresponded with published data. 4,9,25,26 The incidence of late grade ≥2 GI toxicity was 17% (IGRT) vs. 11% (non-IGRT), and only one patient suffered from rectal bleeding 12 months after treatment. There were no significant differences between treatment groups in regard to late grade ≥2 GU toxicity.…”

“…In the literature, acute (grade 2/3) genitourinary (GU) and gastrointestinal (GI) side effects have been reported in 30-50% of cases, and severe side effects, including chronic rectal bleeding ≥ grade 2, have been reported in 6-20% of patients. 4,5 Several studies analyzed the inter-and intrafractional displacements of the prostate, which ranged from 0.2 to 21 mm 6 depending on rectal and bladder filling. Our prospective analysis of 66 prostate cancer patients demonstrated that standardized prostate immobilization using an endorectal balloon significantly reduced organ motion.…”